Accordng to the long-awaited outcomes of the companyR17;s US clinical research, which were released on Wednesday, AstraZeneca Plc’s Covid-19 vaccine demonstrated 74 percent efficacy in terms of preventing symptomatic disease, with efficacy increasing to 83.5 percent in those aged 65 and older.
Despite the fact that the overall efficacy figure of 74 percent was lower than the interim 79 percent figure provided by the British drugmaker in March, AstraZeneca amended the figure a few days later to 76 percent in response to rare public criticism from health experts who claimed the figure was based on “outdated information.”
The study involved over 26,000 participants from the United States, Chile, and Peru, who were given two doses of the vaccine about a month apart in the course of the study. The New England Journal of Medicine published a report on the studyR17;s findings.
When comparing the roughly 17,600 participants who received the immunisation with the 8,500 volunteers who received the placebo, there were no cases of severe or critical symptomatic Covid-19. Aside from that, there were two deaths in the placebo group, whereas there were none in the vaccine group.
According to Dr. Anna Durbin, a vaccination researcher from Johns Hopkins University who was also one of the studyR17;s investigators, “I was pleasantly surprised” by the overall outcome of the study. Her research also revealed that it was “very protective against major illness and hospitalisation.”
There have been no reports of thrombosis associated with thrombocytopenia, a rare but serious blood clotting adverse effect associated with the AstraZeneca vaccine developed in partnership with Oxford University researchers, according to the company.
At the end of July, AstraZeneca stated that it would seek full approval from the United States Food and Drug Administration rather than requesting emergency use authorization. A media event was held at the time and CEO Pascal Soriot expressed hope that the vaccine may still play a role in the United States despite the fact that the process was taking significantly longer than anticipated.
The vaccine, Vaxzevria, has been authorised for use in more than 170 countries. According to a spokesman from the corporation, the company intends to submit an application for US clearance later this year.
In the United States, Durbin believes that Vaxzevria will not be extensively used, but he feels that FDA clearance “gives them gravitas.”